Thông tin thuốc gốc
Chỉ định và Liều dùng
Prophylaxis of puerperal lactation
Adult: 2.5 mg on the day of delivery followed by 2.5 mg bid for 14 days.

Parkinson's disease
Adult: As adjunct to levodopa: 1st wk: Initially, 1-1.25 mg at night; 2nd wk: 2-2.5 mg at night; 3rd wk: 2.5 mg bid; 4th wk: 2.5 mg tid, then increased by 2.5 mg every 3-14 days as required. Maintenance: 10-30 mg daily.

Hypogonadism, Galactorrhoea, Infertility
Adult: Initially, 1-1.25 mg at night, increased to 2-2.5 mg at night after 2-3 days, and subsequently increased by 1-2.5 mg every 2-3 days up to 2.5 mg bid or more if necessary. Max: 30 mg daily.

Prolactinoma (prolactin secreting adenoma)
Adult: Initially,1-1.25 mg at night, increased gradually to 2-2.5 mg daily at 2-3 days interval, then 2.5 mg 8 hrly, 2.5 mg 6 hrly and 5 mg 6 hrly. Max: 30 mg daily.
Child: 7-17 yr Initially, 1 mg bid or tid, may gradually increase according to response. Max: 7-12 yr 5 mg daily; ≥13 yr 20 mg daily.

Adult: Initially, 1-1.25 mg at night, increased gradually to 2-2.5 mg daily at 2-3 days interval then 2.5 mg 8 hrly, 2.5 mg 6 hrly and 5 mg 6 hrly.
Child: 7-17 yr Initially, 1.25 mg bid or tid, may gradually increase according to response. Max: 7-12 yr 10 mg daily; ≥13 yr 20 mg daily.

Suppression of lactation
Adult: 2.5 mg daily for 2-3 days, increased to 2.5 mg bid for 14 days.
Cách dùng
Should be taken with food.
Chống chỉ định
Uncontrolled HTN, hypertensive disorders of pregnancy (including eclampsia, pre-eclampsia or pregnancy-induced HTN), HTN post-partum and in the puerperium. Coronary artery disease, other severe CV disorders, symptoms or history of severe psychiatric disorders when used for the suppression of lactation or other non-life-threatening indications. Evidence of cardiac valvulopathy (long-term therapy). Lactation.
Thận trọng
Patient w/ parkinsonian syndrome who manifest mild degrees of dementia or w/ history of MI and a residual atrial, nodal or ventricular arrhythmia, pleuropulmonary signs and symptoms, history of psychosis, CV disease, Raynaud’s syndrome, history of peptic ulcer. Renal or hepatic impairment. Childn. Pregnancy.
Tác dụng không mong muốn
Nausea, vomiting, drowsiness, orthostatic hypotension, Raynaud’s syndrome, erythromelalgia, arrhythmias, exacerbation of angina, headache, nasal congestion, dry mouth, constipation, diarrhoea, altered LFTs, dyskinaesia, GI bleeding, psychosis, hallucinations, delusions, confusion, pericarditis, pleural thickening and effusions, sudden sleep onset, hypersexuality, visual disturbance, tinnitus, hair loss. Very rarely, HTN, MI, seizures or stroke.
Thông tin tư vấn bệnh nhân
This drug may cause somnolence and/or sudden sleep onset, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Monitor for pituitary enlargement, visual field to detect secondary field loss in macroprolactinoma fibrotic disease; BP and heart rate (at baseline and periodically), GI bleeding and pregnancy test during amenorrheic period.
Quá liều
Symptoms: Vomiting, nausea, dizziness, hypotension, postural hypotension, tachycardia, drowsiness, somnolence, lethargy, confusion and hallucination. Management: Symptomatic and supportive treatment. Administer activated charcoal; may perform gastric lavage if intake is very recent. May give metoclopramide for emesis or hallucinations.
Tương tác
Increased plasma level w/ erythromycin and other macrolide antibiotics. Effects of antihypertensives may be potentiated. Diminished therapeutic effect w/ dopamine antagonists such as psychotropics (e.g. phenothiazines, butyrophenones, thioxanthenes). Additive neurologic effect w/ levodopa. Reduced prolactin-lowering effect w/ metoclopramide and domperidone. Potentially severe adverse effects may occur w/ concomitant use of other ergot alkaloids.
Tương tác với thức ăn
Food reduces nausea caused by bromocriptine. Alcohol reduces tolerance to bromocriptine.
Tác dụng
Mechanism of Action: Bromocriptine is a dopamine D2 agonist which activates postsynaptic dopamine receptors in the tuberoinfundibular pathway that inhibits the secretion of prolactin from the anterior pituitary and may lower blood level of growth hormone. It also stimulates nigrostriatal pathways in the corpus striatum to enhance coordinated motor control.
Absorption: Rapidly absorbed from the GI tract. Bioavailability: Approx 6%. Time to peak plasma concentration: W/in 1-3 hr.
Distribution: Plama protein-binding: 90-96%, mainly albumin.
Metabolism: Undergoes extensive hepatic first-pass metabolism; converted to lysergic acid and peptides via hydrolysis.
Excretion: Via faeces (approx 82%) and urine (approx 2-6%). Elimination half-life: Biphasic: Approx 4-4.5 hr; 15 hr.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Bromocriptine, CID=31101, (accessed on Jan. 21, 2020)

Bảo quản
Store below 25°C. Protect from light.
Phân loại MIMS
Thuốc trị bệnh Parkinson / Các thuốc khác ảnh hưởng sự điều hòa hormon
Phân loại ATC
G02CB01 - bromocriptine ; Belongs to the class of prolactine inhibitors. Used to suppress lactation.
N04BC01 - bromocriptine ; Belongs to the class of dopamine agonist. Used in the management of Parkinson's disease.
Tài liệu tham khảo
Anon. Bromocriptine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 28/06/2016.

Bromocriptine Tablet (Paddock Laboratories, LLC). DailyMed. Source: U.S. National Library of Medicine. Accessed 28/06/2016.

Buckingham R (ed). Bromocriptine Mesilate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 28/06/2016.

Joint Formulary Committee. Bromocriptine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 28/06/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Bromocriptine Mesylate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 28/06/2016.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Bromocriptine từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Bromocriptin-Richter
  • Bromokriptin
  • Parlodel
  • Serocryptin
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in